Illinois Municipal Retirement Fund Purchases 6,802 Shares of Xencor, Inc. (NASDAQ:XNCR)

Illinois Municipal Retirement Fund grew its position in shares of Xencor, Inc. (NASDAQ:XNCR) by 25.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 33,198 shares of the biopharmaceutical company’s stock after buying an additional 6,802 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Xencor were worth $763,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. KBC Group NV lifted its holdings in Xencor by 63.5% during the third quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 1,213 shares during the period. Thrivent Financial for Lutherans increased its position in shares of Xencor by 127.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 116,369 shares of the biopharmaceutical company’s stock valued at $2,340,000 after purchasing an additional 65,180 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Xencor during the 3rd quarter worth $362,000. Intech Investment Management LLC purchased a new position in shares of Xencor in the 3rd quarter worth about $368,000. Finally, Charles Schwab Investment Management Inc. grew its position in Xencor by 7.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 626,988 shares of the biopharmaceutical company’s stock valued at $12,609,000 after buying an additional 40,788 shares during the period.

Insider Activity at Xencor

In related news, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the sale, the director now owns 9,140 shares in the company, valued at approximately $247,054.20. This trade represents a 13.46 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.23% of the stock is owned by corporate insiders.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $14.46 on Tuesday. The stock has a fifty day moving average of $19.23 and a 200-day moving average of $20.69. The stock has a market cap of $1.01 billion, a PE ratio of -4.52 and a beta of 0.70. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. Xencor, Inc. has a fifty-two week low of $14.18 and a fifty-two week high of $27.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. Equities research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Analyst Ratings Changes

XNCR has been the topic of several research reports. StockNews.com lowered shares of Xencor from a “hold” rating to a “sell” rating in a research report on Wednesday, February 26th. Wedbush reiterated an “outperform” rating and issued a $38.00 price objective on shares of Xencor in a research note on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. BMO Capital Markets restated an “outperform” rating and issued a $34.00 target price (up from $32.00) on shares of Xencor in a research note on Friday, November 8th. Finally, Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $20.00 to $30.00 in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.38.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.